Vice President and Head of Emerging Infectious Diseases and Scientific Strategy
Swati Gupta leads the integration of IAVI’s research and development portfolio and the organization’s global network of laboratories. She leverages IAVI’s platforms and expertise to expand product development efforts to areas beyond HIV.
Before joining IAVI, Gupta was an executive director with Merck Vaccines, working on the development of innovative partnership models to address issues related to vaccine science and technology. In this role, she worked with stakeholders to accelerate Ebola vaccine development during the 2014-16 epidemic in West Africa. Previously, Gupta was in the department of epidemiology at Merck Research Laboratories, where she designed and led international prospective cohort studies of vaccine and infectious disease products in development. She also worked in HIV surveillance at the Communicable Disease Surveillance Centre in the U.K., and in the New York City Department of Health Bureau of Tuberculosis Control.
She holds a B.A. from Washington University in St. Louis, an M.P.H. from the Yale School of Medicine, and a Dr.PH. in epidemiology from the Johns Hopkins Bloomberg School of Public Health.